The mutagenicity of urine fractions from patients administered antineoplastic therapy

• Published in: Toxicology letters Vol. 40; no. 3; p. 257
• Main Authors: Monteith, D K, Connor, T H, Benvenuto, J A, Fairchild, E J, Theiss, J C
• Format: Journal Article
• Language: English
• Published: Netherlands 01.03.1988
• Subjects: Antineoplastic Agents - toxicity; Cisplatin - toxicity; Cisplatin - urine; Cyclophosphamide - toxicity; Cyclophosphamide - urine; Doxorubicin - toxicity; Doxorubicin - urine; Humans; Mitomycins - toxicity; Mitomycins - urine; Mutagens - analysis
• ISSN: 0378-4274; 1879-3169
• DOI: 10.1016/0378-4274(88)90049-5

A concern among hospital personnel is their exposure to mutagenic drugs and in the incidental exposures that could occur in caring for the patients. In a recent published study the mutagenicity of urine from patients administered antineoplastic drugs was determined and techniques were developed to chemically inactivate the mutagenicity. A question still remained as to what components of the excreted urine were mutagenic. Urine samples from patients receiving mutagenic drugs were fractionated by high pressure liquid chromatography (HPLC) to then assay by the Ames test the collected and concentrated fractions to determine what were the mutagenic compounds in the urine. Urine samples from patients on single agent cancer treatment with cisplatin, cyclophosphamide, doxorubicin and mitomycin C were assayed. In general, all urine samples containing the cytotoxic agents studied were mutagenic because of the presence of the parent compound, except cyclophosphamide which requires activation and therefore an active metabolite was the major mutagenic constituent in the urine sample. This data indicates that the mutagenicity of urine from patients receiving these antineoplastic agents is the result of the parent compound or a single major metabolite.